TY - JOUR A1 - Kelm, Matthias A1 - Anger, Friedrich A1 - Eichlinger, Robin A1 - Brand, Markus A1 - Kim, Mia A1 - Reibetanz, Joachim A1 - Krajinovic, Katica A1 - Germer, Christoph-Thomas A1 - Schlegel, Nicolas A1 - Flemming, Sven T1 - Early Ileocecal Resection Is an Effective Therapy in Isolated Crohn’s Disease JF - Journal of Clinical Medicine N2 - Despite the increasing incidence and prevalence of Crohn’s Disease (CD), no curative options exist and treatment remains complex. While therapy has mainly focused on medical approaches in the past, growing evidence reveals that in cases of limited inflammation, surgery can suffice as an alternative primary treatment. We retrospectively assessed the disease course and outcomes of 103 patients with terminal Ileitis who underwent primary surgery (n = 29) or received primary medical treatment followed by surgery (n = 74). Primary endpoint was the need for immunosuppressive medication after surgical treatment (ileocecal resection, ICR) during a two-years follow-up. Rates for laparoscopic ICR were enhanced in case of early surgery, but no differences were seen for postoperative complications. In case of immunosuppressive medication, patients with ICR at an early state of disease needed significantly less anti-inflammatory medication during the two-year postoperative follow-up compared to patients who were primarily treated medically. Furthermore, in a subgroup analysis for patients with localized ileocecal disease manifestation, early surgery consistently resulted in a decreased amount of medical therapy postoperatively. In conclusion primary ICR is safe and effective in patients with limited CD, and the need for immunosuppressive medication during the postoperative follow-up is low compared to patients receiving surgery at a later stage of disease. KW - Crohn’s Disease KW - surgical therapy KW - ileocecal resection Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-228822 SN - 2077-0383 VL - 10 IS - 4 ER - TY - JOUR A1 - Kollmann, Cathérine T. A1 - Pretzsch, Elise B. A1 - Kunz, Andreas A1 - Isbert, Christoph A1 - Krajinovic, Katica A1 - Reibetanz, Joachim A1 - Kim, Mia T1 - Anorectal angle at rest predicting successful sacral nerve stimulation in idiopathic fecal incontinence—a cohort analysis JF - International Journal of Colorectal Disease N2 - Purpose Sacral nerve stimulation is an effective treatment for patients suffering from fecal incontinence. However, less is knownabout predictors of success before stimulation. The purpose of this study was to identify predictors of successful sacral nervestimulation in patients with idiopathic fecal incontinence. Methods Consecutive female patients, receiving peripheral nerve evaluation and sacral nerve stimulation between September2008 and October 2014, suffering from idiopathic fecal incontinence were included in this study. Preoperative patient’scharac-teristics, anal manometry, and defecography results were collected prospectively and investigated by retrospective analysis. Mainoutcome measures were independent predictors of treatment success after sacral nerve stimulation. Results From, all in all, 54 patients suffering from idiopathic fecal incontinence receiving peripheral nerve evaluation, favorableoutcome was achieved in 23 of 30 patients after sacral nerve stimulation (per protocol 76.7%; intention to treat 42.6%). From allanalyzed characteristics, wide anorectal angle at rest in preoperative defecography was the only independent predictor offavorable outcome in multivariate analysis (favorable 134.1 ± 13.9° versus unfavorable 118.6 ± 17.1°). Conclusions Anorectal angle at rest in preoperative defecography might present a predictor of outcome after sacral nervestimulation in patients with idiopathic fecal incontinence. KW - sacral nerve stimulation KW - idiopathic fecal incontinence KW - sacral neuromodulation KW - anorectal angl Y1 - 2020 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-232379 SN - 0179-1958 VL - 35 ER - TY - THES A1 - Krajinovic, Katica T1 - Outcome und prognostische Faktoren nach Resektion von gastrointestinalen Stromatumoren T1 - Outcome and prognostic factors after resection of gastrointestinal stromal tumors N2 - Gastrointestinale Stromatumoren (GIST) sind die häufigsten mesenchymalen Tumoren des Gastrointestinaltraktes. Diese Tumoren wurden früher meist als Leiomyome, Leiomyosarkome oder aggressive Neurinome klassifiziert. Die Entdeckung des c-kit Onkogens CD 117 auf der Oberfläche mesenchymaler Tumoren führte zu einer entscheidenden histologischen Differenzierung dieser Tumorgruppe. 1998 wurden gastrointestinale Stromatumoren – GIST als eigenständige Tumorentität neu definiert. Gastrointestinale Stromatumoren stammen aus den interstitiellen Zellen von Cajal. Diese sogenannten Schrittmacherzellen wurden erstmals 1893 von dem spanischen Neuroanatomen und Nobelpreisträger Santiago Ramon y Cajal (1852-1934) beschrieben. Obwohl die interstitiellen Cajal-Zellen (ICC) non-neuronale Zellen mesenchymalen Ursprungs sind, werden sie dennoch als intestinale Schrittmacherzellen bezeichnet, da sie offensichtlich in der Lage sind, neuronale Stimuli auf glatte Muskelzellen zu übertragen und sogenannte „slow waves“ zu generieren. Die Cajal-Zellen bilden dreidimensionale Netzwerke innerhalb der Tunica muscularis und sind sowohl untereinander als auch mit Muskel- und Nervenzellen durch Gap Junctions verbunden. Die Inzidenz der klinisch signifikanten gastrointestinalen Tumoren beträgt 10-20 pro Million pro Jahr . Diese Zahl zugrundegelegt sind dies in Deutschland etwa 1200 Erkrankungen pro Jahr. Das mediane Alter bei Erkrankungsbeginn liegt zwischen 55 und 65 Jahren. Eine familiäre Disposition für GIST wurde beschrieben. Gastrointestinale Stromatumoren können zudem in jedem Anteil des Gastrointestinaltraktes auftreten, bevorzugt im Magen sowie im Dündnarm, jedoch auch im Ösophagus, Anorektum sowie extraluminal im Bereich des Peritoneums. N2 - Following the discovery of activating c-kit mutations and demonstration of c-kit (CD 117) immunoexpression on the surface of tumor cells in the majority of mesenchymal GI neoplasms formerly calssified as smooth muscle or neurogenic neoplasms, gastrointestinal stromal tumors (GISTs) were redefined as an independent tumor entity. The incidence of GISTs is estimated to be 14.5 cases per million people per year1. Accordingly, about 1200 new cases are diagnosed in Germany every year. Gain-of-function mutations in c-kit result in overexpression of the receptor tyrosine kinase on the cell surface with a consequent ligand-independent activation of the tyrosine kinases cascade. These novel findings represented the base for the targeted molecular therapy with the tyrosine kinase inhibitor imatinib (Glivec®), an agent that is easy-to-take orally and a highly effective systemic therapy that soon became available for patients with locally advanced and metastatic disease. However, the surgical R0 resection continues to be the treatment of choice for resectable tumors. A majority of GISTs could be resected by local excision. Multivisceral enbloc resection represents a relatively rare event and is necessary for huge GISTs that have involved neigbouring organs. Furthermore, surgical metastasectomy and ablative procedures are additional options for patients with solitary metastases or residual, metabolically active tumor masses and should be discussed individually. Taking in consideration that at least one half of patients with initial response to imatinib would ultimately develop drug resistance it is mandatory to be able to accurately predict the likelihood of tumor recurrence and/or metastases after R0 resection of GIST. Diverse prognostic factors that would predict the development of recurrence and/or metastases after R0 resection of GIST have been evaluated by several research groups worldwide, in particular for the category of high-risk tumors. The question whether adjuvant treatment with imatinib is indicated in patients with R0-resected high-risk GISTs has not yet been conclusively settled. However, results from current studies relating to this topic are anticipated in the near future. The objectives of this large monocentric trial were to evaluate the outcome after surgical resection and to determine prognostic factors for tumor relaps and tumor-related death. KW - Gist KW - Stromatumor KW - Resektion KW - Prognosefaktor KW - Stromal tumor KW - resection KW - prognostic factor Y1 - 2009 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-45244 ER -